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ABSTRACT 
 
The aim of this study was to prepare and evaluate the pellets, containing a highly soluble drug (ascorbic acid), by 
the extrusion-spheronization process and coated with a release controlling polymer. The coating (undertaken in a 
fluid bed) was applied to three batches of the pellets with a dispersion of Kollicoat SR 30 D, with each batch of 
pellets receiving a different level of polymer (5.07; 8.26 and 10.35%). The coated pellets were evaluated for 
sphericity by imaging analysis and comparative dissolution profile with a product commercially available in Brazil. 
All of the evaluated samples presented adequate physical properties and the dissolution profile of those coated with 
5.07% of polymer proved to be similar to that of the commercially available brand name.  
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INTRODUCTION 
 
Among the different possibilities for the oral 
administration of pharmaceutical drugs, pellets 
have garnered much attention due to their inherent 
technological and therapeutical advantages, such 
as efficient absorption and distribution via the 
gastro-intestinal tract, decreased risk of localized 
irritation and their spherical format, which makes 
coating for the controlled release of active agents 
easier, among other things (Newton et al., 2002; 
Ford et al., 2003; Siepmann et al., 2004). 
Generally, controlled-release pellets are prepared 
by coating an inert nucleus first with an atomized 
solution or suspension containing the active agent 
of the drug and then with the substances that can 
control its dissolution process. A second method 
consists of the preparation of pellets containing a 
drug, which are then coated with an aqueous 
polymer dispersion, in a single uniform layer of 
film.  In the latter case, the drug is inserted into a 
nucleus which is then coated with a porous layer 
responsible for controlling the speed of dissolution 
(Nastruzzi et al., 2000; Ford et al., 2003). 
The coating of solid dosage forms with the 
application of aqueous or organic polymer 
dispersions is a well-known procedure in the 
pharmaceutical industry. However, toxicity, 
environmental concerns and shorter processing 
times all mean that aqueous dispersions are more 
commonly used (Dashevsky et al., 2005).  
The formation of a uniform, rupture-less film 
created from an aqueous dispersion basically 
depends on the polymer used and the minimum 
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film-forming temperature - MFT (Siepmann et al., 
2006). Dosage forms coated in polymers with 
elevated MFT values generally undergo thermal 
treatment for short periods of time, called the 
“curing” process, so that the complete coalescence 
and formation of the film may occur. Plasticizers 
are often added to these dispersions in order to 
reduce MFFT values and improve the formation of 
the film. However, the curing process and the 
addition of plasticizers may alter the dissolution 
profile of the drug (Bodmeier and Paeratakul 
1994). 
Kollicoat SR 30D is a commercial alternative that 
enables solid dosage forms to be coated without 
the material having to undergo the curing process 
and without the addition of plasticizers to the 
formula (Dashevski et al., 2005). Shao et al. 
(2002) prepared controlled-release pellets by 
coating the inert nuclei with a Kollicoat SR 30D 
dispersion associated to the drug 
(diphenhydramine hydrochloride). The dissolution 
profile presented an effective control over the 
release of the drug. By combining Kollicoat SR 
30D and Kollicoat MAE (enteric release 
dispersion) in a 90:10 proportion to coat verapamil 
hydrochloride pellets, Dashevski et al., (2004) 
demonstrated that pH-independent release was 
possible for this drug. Dashesvki et al. (2005) 
evaluated three drugs (ibuprofen, propranolol and 
ambroxol hydrochloride) and reported the physical 
and chemical characteristics of Kollicoat SR 30D 
in film formation without the addition of a 
plasticizer, in addition to its flexibility in the 
development of controlled-release dosage forms. 
Gehbre-Sellassie et al. (1988) found that the 
aqueous solubility of a drug was an important 
parameter that needed to be evaluated during the 
preparation of coated controlled-release pellets, 
because highly soluble drugs were generally 
released faster than those with lower solubility in 
water, which presented a great challenge for the 
formulator.  
The aim of this study was to evaluate the use of 
Kollicoat SR 30 D, a polyvinylacetate-based 
commercial product, in the coating of the pellets 
obtained by the extrusion-spheronization process 
containing a highly soluble drug (ascorbic acid), 
and to determine the level of coating necessary to 
achieve an adequate level of control over the 
release of the drug.  
 
 
MATERIAL AND METHODS 
 
Pharmaceutical-grade raw materials were obtained 
from the local suppliers and were used as received. 
The pellets were prepared with 101 
microcrystalline cellulose– Microcel® 101 
(Blanver, Cotia, Brazil), tartaric acid, 
polyvinylpyrrolidone K 30 and ascorbic acid 
(Synth São Paulo, Brazil). The aqueous dispersion 
of Kollicoat® SR 30 D was kindly donated by 
BASF S.A. (São Paulo, Brazil). As a reference 
product, commercially available pellets (C) 
containing ascorbic acid packed in hard gelatin 
capsules was obtained (Cebion - batch 1041181A, 
Merck SA, Brazil). 
 
Pellet preparation  
The pellets were prepared (50.96% Microcel® 101, 
10.22% polyvinylpyrrolidone K 30, 0.6% tartaric 
acid, 38.22% ascorbic acid and purified water 
35mL%) by the extrusion- spheronization process 
(Extruder 20, Caleva, Dornset, UK), spheronized 
(Spheronizer 250, Caleva, Dornset, UK) into 25 
cm-diameter cross-hatch pattern discs at 1000 rpm 
for 10 minutes. The pellets were dried in a Hüttlin 
Mycrolab fluid bed (Hüttlin, Steinen, Germany) 
for 30 minutes. Then the material obtained was 
sorted by five sequential sieves (Bashaiwoldu et 
al., 2004). The fraction covering the interval from 
0.5 to 1.4 mm was separated into two sections, the 
first called uncoated pellets (UC) and the second 
chosen for coating. 
 
Coating of pellets 
Three batches of 50 g pellets (K1, K2 and K3) 
were coated by atomizing the dispersion of 68.8% 
Kollicoat® SR 30 D (27% polyvinyl acetate, 2.7% 
povidone and 0.3% de sodium lauryl sulfate), 
1.55% talc, 0.23% titanium dioxide and 29.42% 
purified water for 45 minutes for K1, 90 minutes 
for K2 and 160 minutes for K3. The coating was 
done in a Hüttlin Mycrolab fluid bed (Hüttlin, 
Steinen, Germany) with air input and output 
temperatures of 50.9°C and 33.5°C, respectively, 
air flow of 17.5m3/h, product temperature of 35° 
C, and atomization pressure of 1 bar, needle no.6 
and peristaltic pump speed of 1.1mL/min. At the 
end of each process, the pellets were dried for 
fifteen minutes in the same equipment and 
conditions. 
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Imaging analysis 
Samples of UC and K1, K2 and K3 pellets were 
analyzed by a JEOL JSM-6360 LV scanning 
electron microscope (Tokyo Japan) for a surface 
evaluation (before and after coating). Samples 
from the same batches were also examined with a 
CCD Olympus SZ stereo microscope (Olympus 
America Inc., New York, USA). The digital 
images were processed by the software Image pro-
plus® (version 1.2, Media Cybernetics, Silver 
Spring, MD, USA), where the perimeter, the 
average, minimum and maximum diameters were 
ascertained (used in the determination of 
sphericity or shape factor eR described by 
Podczeck et al., 1999), as well as the ratio radius. 
 
Ascorbic acid content  
The ascorbic acid content for the different batches 
was ascertained (sample of 100mg) by high 
performance liquid chromatography-HPLC 
(Varian, Palo Alto, USA), mobile phase (90% of 
0.2% metaphosphoric acid in purified water, 8% 
methanol and 2% acetonitril, all of 
chromatographic grade), column C18, 5µm, 250 x 
4.6 mm; 20 µL looping, UV-VIS Prostar 320 
detector and data handled by Workstation Star 
6.0.  
 
Evaluation of the coating 
The level of coating for each batch was calculated 
by subtracting the ascorbic acid content 
determined in the coated pellets from that 
ascertained for the uncoated pellets (Amighi and 
Moës, 1996).  
 
Dissolution profile 
The dissolution profile of the UC, K1, K2, K3 and 
C pellets was carried out in the Erweka DT80 
(Erweka GmbH, Bizen, Germany) dissolution 
tester, equipped with an apparatus 1 (basket) 
rotating at 100 rpm. The dissolution medium 
consisted of 900 ml of 0.1M hydrochloric acid for
the first hour of the test. For the subsequent five 
hours, a 0.06M phosphate buffer (pH 6.8) was 
used as a dissolution medium. Samples of 10 ml 
were drawn after 1, 5, 10, 20, 40, 60, 120, 180, 
240, 300 and 360 minutes, filtered (Millipore HV 
JBR610245-Millipore, Massassuchets, USA), and 
then underwent HPLC using the aforementioned 
conditions. The profiles obtained were compared 
by the determination of the factors of similarity 
and difference (f2 and f1), with the commercially 
available product, C, as a reference (Guidance, 
1997). 
 
 
RESULTS AND DISCUSSION  
 
The shape of the pellets was evaluated by the ratio 
radius and the parameter еR, whose value of 0.6 
was the minimum limit to describe a particle with 
good sphericity, which corresponded to a 
maximum ratio between radii of 1.1 (Podczeck 
and Newton 1994 and 1995; Podczeck et al., 
1999). However, according to Vervaet and Remon 
(1996), this value should be less or equal to 1.2. 
The sphericity values for UC (Table 1) were lower 
than that indicated; however they were apt to be 
coated (Fig. 1). For the batches K1, K2 and K3, a 
gradual increase in the eR value was noted (Table 
1), accompanied by the reduction in the ratio 
radius, indicating a possible improvement in the 
sphericity with increase of the roughness (Fig.1).  
This behavior could be linked to the fluid bed 
coating process, which resulted in a rounding of 
the particles due to the uniform deposition of the 
film, thus correcting the imperfections of the 
spheronization process. The advent of roughness 
could be linked to the fluid bed coating process 
and the length of time that each batch was 
submitted to the process. In these apparatuses, 
solvent evaporation occurs rapidly. Dyer et al. 
(1994) noted that processes of this nature led to 
greater roughness on the surface of the pellets. 
 
 
Table 1 – Values of the ratio radius and sphericity (еR) of the pellets UC, K1, K2, K3 and C 
 UC K1 K2 K3 C 
Ratio radius 1,13±0,05 1,12±0,17 1,08±0,20 1,10±0,04 1,04±0,01 
еR  0,55±0,07 0,56±0,09 0,60±0,05 0,61±0,09 0,66±0,05 
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Figure 1 - Image analysis (SEM-25keV) of the surface of the pellets UC, K1, K2 e K3. 
 
 
Thus, the pellets in which the coating time was 
higher remained under the influence of the air flow 
and the temperature of the process for a longer 
period of time, which led to a "shrinkage" of the 
coating layer. According to Amighi and Moës 
(1996), the content of the drug present in the 
uncoated dosage form is a reference to ascertain 
the level of coating of the coated version of the 
same dosage form. The values described in Table 
2 demonstrated a reduction in the ascorbic acid 
content in the K1, K2 and K3 sequence, indicating 
a proportionately growing layer of coating. This 
outcome was expected, since the coating times 
were different for all of the batches (45, 60 and 
160 minutes, respectively). For the UC pellets, the 
dissolution was higher than 80% in the first 15 
minutes of the test, a characteristic of ready-
release products. 
In the K1, K2 and K3 batches, coated with 
Kollicoat SR 30 D, there was an alteration in the 
dissolution profile compared to UC, demonstrating 
the influence of the polymer layer in the 
dissolution of the drug. The reduction in the 
percentage of ascorbic acid dissolved was 
proportional to the level of coating (Fig. 2), where 
the batches with a higherlayer of coating presented 
lower drug dissolution, exactly what was described 
by Shao et al., (2002) and Bodmeier and 
Pearnchob (2003) and Dashevsky et al., (2004). 
For the commercially available product C, the 
dissolution profile ascertained was compatible 
with a controlled-release dosage form. The 
comparison the dissolution profiles of K1 and C 
presented very similar values of dissolved 
percentage point by point, differing only in the 
initial collection times of the test (up to time 
number 40), where K1 presented higher retention 
of the drug. Through the determination of the 
factors of difference (f2) and similarity (f1) (Table 
2), the proximity between these profiles was 
evident (Guidance, 1997). Thus, the 5.07% level 
of coating used in K1 was sufficient and adequate 
to control the release of ascorbic acid as it 
presented a dissolution profile compatible with the 
commercial product, which enabled a gradual 
release over a long period of time. 
 
Table 2 - Values of the ascorbic acid content of the pellets UC, K1, K2 and K3, their levels of coating, similarity 
and difference factors (f1 and f2) among dissolution profile K1, K2 e K3 
 UC K1 K2 K3 
Ascorbic acid content (mg%) 37.45±0.57 32.38±2.27 29.19±1.73 27.10±0.85 
Coating level (mg%) - 5.07 8.26 10.35 
f1 - 13.52 67.25 93.22 
f2 - 62.05 28.83 20.88 
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Figure 2 – Dissolution profile of pellets K1, K2, K3, C and UC. 
 
 
 
CONCLUSION 
 
The use of the dispersion of Kollicoat SR 30 D in 
the coating of the pellets containing ascorbic acid 
resulted in effective control over the release of the 
drug. An approximately 5% level of coating was 
necessary for this. In these conditions, the pellets 
produced by the extrusion/spheronization process 
were apparently similar, in terms of dissolution of 
ascorbic acid, to the commercially available 
reference product. 
The amount of drug dissolved was directly related 
to the level of coating applied, as evidenced by the 
performance of the batch with the highest level of 
coating (K3). This enabled the dissolution profile 
of drugs with high solubility in water to be 
modified by altering the thickness of the layer of 
coating without altering the release process 
mechanism. 
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